Database Commons

a catalog of biological databases

e.g., animal; RNA; Methylation; China

Database information

TP53 mutation database

General information

Description: TP53 mutation database is a a regularly updated resource centre for TP53 mutations and mutants.
Year founded: 1993
Last update: 2017-08
Version: R8
Real time : Checking...
Country/Region: France
Data type:
Data object:
Database category:
Major organism:

Contact information

University/Institution: Sorbonne University
Address: Université Pierre et Marie Curie-Paris6, 75005 Paris, France and Dept of Oncology Pathology, Karolinska Institute, Stockholm, Sweden
City: Paris
Country/Region: France
Contact name (PI/Team): Thierry Soussi
Contact email (PI/Helpdesk):

Record metadata

Created on: 2015-06-20
Curated by:
Dong Zou [2019-01-04]
Fatima Batool [2018-12-27]
Lina Ma [2016-04-15]
Mengwei Li [2016-02-15]
Guangyu Wang [2015-06-26]


All databases:
296/4549 (93.515%)
Health and medicine:
57/917 (93.893%)
Total Rank

Community reviews

Not Rated
Data quality & quantity:
Content organization & presentation
System accessibility & reliability:

Word cloud


Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing. [PMID: 29696732]
Tikkanen T, Leroy B, Fournier JL, Risques RA, Malcikova J, Soussi T.

Accurate annotation of genomic variants in human diseases is essential to allow personalized medicine. Assessment of somatic and germline TP53 alterations has now reached the clinic and is required in several circumstances such as the identification of the most effective cancer therapy for patients with chronic lymphocytic leukemia (CLL). Here, we present Seshat, a Web service for annotating TP53 information derived from sequencing data. A flexible framework allows the use of standard file formats such as Mutation Annotation Format (MAF) or Variant Call Format (VCF), as well as common TXT files. Seshat performs accurate variant annotations using the Human Genome Variation Society (HGVS) nomenclature and the stable TP53 genomic reference provided by the Locus Reference Genomic (LRG). In addition, using the 2017 release of the UMD_TP53 database, Seshat provides multiple statistical information for each TP53 variant including database frequency, functional activity, or pathogenicity. The information is delivered in standardized output tables that minimize errors and facilitate comparison of mutational data across studies. Seshat is a beneficial tool to interpret the ever-growing TP53 sequencing data generated by multiple sequencing platforms and it is freely available via the TP53 Website, or directly at

Hum Mutat. 2018:39(7) | 2 Citations (from Europe PMC, 2020-03-28)
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. [PMID: 28254861]
Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF, Taschner PE, Hainaut P, Soussi T.

Accurate assessment of gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li-Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of information on cancer gene alterations and have confirmed as the most commonly mutated gene in human cancer. Analysis of a database of 70,000 variants reveals that the two newly discovered exons of the gene, exons 9? and 9?, generated by alternative splicing, are the targets of inactivating mutation events in breast, liver, and head and neck tumors. Furthermore, germline rearrange-ments in intron 1 of are associated with LFS and are frequently observed in sporadic osteosarcoma. In this context of constantly growing genomic data, we discuss how screening strategies must be improved when assessing status in clinical samples. Finally, we discuss how alterations should be described by using accurate nomenclature to avoid confusion in scientific and clinical reports. .

Cancer Res. 2017:77(6) | 17 Citations (from Europe PMC, 2020-03-28)
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. [PMID: 23161690]
Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T.

A novel resource centre for TP53 mutations and mutants has been developed ( TP53 gene dysfunction can be found in the majority of human cancer types. The potential use of TP53 mutation as a biomarker for clinical studies or exposome analysis has led to the publication of thousands of reports describing the TP53 gene status in >10,000 tumours. The UMD TP53 mutation database was created in 1990 and has been regularly updated. The 2012 release of the database has been carefully curated, and all suspicious reports have been eliminated. It is available either as a flat file that can be easily manipulated or as novel multi-platform analytical software that has been designed to analyse various aspects of TP53 mutations. Several tools to ascertain TP53 mutations are also available for download. We have developed TP53MULTLoad, a manually curated database providing comprehensive details on the properties of 2549 missense TP53 mutants. More than 100,000 entries have been arranged in 39 different activity fields, such as change of transactivation on various promoters, apoptosis or growth arrest. For several hot spot mutants, multiple gain of function activities are also included. The database can be easily browsed via a graphical user interface.

Nucleic Acids Res. 2013:41(Database issue) | 66 Citations (from Europe PMC, 2020-03-28)
Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. [PMID: 9016527]
Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R.

In recent years, there has been an exponential increase in the number of p53 mutations identified in human cancers. The p53 mutation database consists of a list of point mutations in thep53 gene of human tumors and cell lines, compiled from the published literature and made available through electronic media. The database is now maintained at the International Agency for Research on Cancer (IARC) and is updated twice a year. The current version contains records on 5091 published mutations and is expected to surpass the 6000 mark in the January 1997 release. The database is available in various formats through the European Bioinformatics Institute (EBI) ftp server at: or by request from IARC ( and will be searchable through the SRS system in the near future. This report provides a description of the criteria for inclusion of data and of the current formats, a summary of the relevance ofp53 mutation analysis to clinical and biological questions, and a brief discussion of the prospects for future developments.

Nucleic Acids Res. 1997:25(1) | 152 Citations (from Europe PMC, 2020-03-28)
Database of p53 gene somatic mutations in human tumors and cell lines. [PMID: 7937055]
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sørlie T, Hovig E, Smith-Sørensen B, Montesano R, Harris CC.

A data base is described in which over 2,500 mutations in the p53 gene of human tumors and tumor cell lines are compiled from a systematic search of reports published before 1 January 1994. Data from 1994 are being added intermittently, with a systematic search and update scheduled for December, 1994. The compilation has been deposited with the EMBL Data Library and is available in electronic form free of charge. This report contains a rationale for the compilation, a brief summary of the major findings and a description of the data base.

Nucleic Acids Res. 1994:22(17) | 405 Citations (from Europe PMC, 2020-03-28)